Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsSusan D. Mertins, Susan E. Bates, David G. Covell, Geoffrey W. Patton, Melinda G. Hollingshead, Rao Vishnuvajjalla
Life of this patent
Estimating the term…
Abstract
The present invention features methods of treating a mammalian subject having renal cancer by administration of 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.
Claims20
A method for treating a mammalian patient having renal cell carcinoma, comprising:
- administering to the patient 4-[bis[2-[(methylsulfonyl)oxy] ethyl] amino]-2-methyl-benzaldehyde, or a pharmaceutically acceptable salt thereof in two or more doses, each dose comprising sin between about 0.5 mg/Kg and about 25 mg/kg of 4-[bis[2-[(methylsulfonyl)oxy]ethy]amino]-2-methyl-benzaldehyde or a pharmaceutically acceptable salt thereof, thereby treating the patient.
A method for treating a mammalian patient having renal cell carcinoma, comprising:
- administering to the patient 4-[bis[2-[(methylsulfonyl)oxy] ethyl] amino]-2-methyl-benzaldehyde, or a pharmaceutically acceptable salt thereof in two or more doses, each dose comprising about 1 mg/kg of 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde or a pharmaceutically acceptable salt thereof, thereby treating the patient.
Dependencies are inferred from the claim text.